Page last updated: 2024-12-11
oviedomycin
Description
oviedomycin: an unusual angucyclinone encoded by genes of the oleandomycin-producer Streptomyces antibioticus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
oviedomycin : A member of the class of tetraphenes that is 1,4,7,12-tetrahydrotetraphene substituted by oxo groups at positions 1, 4, 7, and 12, by hydroxy groups at positions 2, 6 and 8, and by a methyl group at position 3. It is a natural product found in Streptomyces antibioticus ATCC 11891 which exhibits cytotoxicity against A549 human lung cancer cells, HepG2 liver cancer cells, and MCF-7 breast cancer cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5323531 |
| CHEBI ID | 156291 |
| SCHEMBL ID | 1007479 |
| MeSH ID | M0434252 |
Synonyms (9)
| Synonym |
|---|
| oviedomycin |
| 439127-45-4 |
| 3-methyl-2,6,8-trihydroxybenzo[a]anthracene-1,4,7,12-tetrone |
| CHEBI:156291 |
| 2,6,8-trihydroxy-3-methyl-benz[a]anthracene-1,4,7,12-tetrone |
| 2,6,8-trihydroxy-3-methyltetraphene-1,4,7,12-tetrone |
| 2,6,8-trihydroxy-3-methyl-1,4,7,12-tetrahydrotetraphene-1,4,7,12-tetrone |
| 4,6,8-trihydroxy-3-methylbenzo[a]anthracene-1,2,7,12-tetrone |
| SCHEMBL1007479 |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.97
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.97 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.92 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |